BioNTech and Bristol Myers Squibb announced a strategic partnership to co-develop and commercialize BNT327, a cancer antibody candidate, in a deal potentially worth up to $11.1 billion.
Key facts
up to $11.1 billionPotential value of the strategic partnership between BioNTech and Bristol Myers Squibb.
Source Context
BioNTech has entered into a strategic partnership with Bristol Myers Squibb to co-develop and commercialize BNT327, a bispecific antibody candidate for cancer treatment, in a deal valued at up to $11.1 billion.
Channel context
View channel Healthtech & Biotech
This signal belongs to the Healthtech & Biotech channel. Browse related signals to see how this development fits into the broader landscape.
115 signals in this channelMy Notes
Sign in to save notes on signals.
Sign In